Lv1
30 积分 2023-08-17 加入
Elucidating Binding Selectivity in Cyclin-Dependent Kinases (CDKs) 4, 6, and 9: Development of Highly Potent and Selective CDK4/9 Inhibitors
1个月前
已完结
Design and Development of Glucocorticoid Receptor Modulators as Immunology Antibody–Drug Conjugate Payloads
1个月前
已完结
Self-Immolative Carbamate Linkers for CD19-Budesonide Antibody–Drug Conjugates
1个月前
已完结
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
3个月前
已完结
Discovery of novel chemotype inhibitors targeting Anaplastic Lymphoma Kinase receptor through ligand-based pharmacophore modelling
3个月前
已完结
Fragment-based discovery of novel phenyltriazolyl derivatives as allosteric type-I1/2 ALK inhibitors with promising antitumor effects
3个月前
已完结
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations
3个月前
已完结
First macrocyclic 3 rd -generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib
3个月前
已完结
Preclinical Evaluation of226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy
4个月前
已关闭
ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
4个月前
已完结
皖公网安备34019202002308
